Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Oct 16;16(10):1467.
doi: 10.3390/ph16101467.

Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment

Affiliations
Review

Bacteriophages and Their Host Range in Multidrug-Resistant Bacterial Disease Treatment

Ka Mun Chung et al. Pharmaceuticals (Basel). .

Abstract

The rapid emergence of multidrug-resistant (MDR) bacteria in recent times has prompted the search for new and more potent antibiotics. Bacteriophages (commonly known as phages) are viruses that target and infect their bacterial hosts. As such, they are also a potential alternative to antibiotics. These phages can be broadly categorized into monovalent (with a narrow host range spectrum and specific to a single bacterial genus) and polyvalent (with a broad host range and specific to more than two genera). However, there is still much ambiguity in the use of these terms, with researchers often describing their phages differently. There is considerable research on the use of both narrow- and broad-host range phages in the treatment of infections and diseases caused by MDR bacteria, including tuberculosis, cystic fibrosis, and carbapenem-resistant Enterobacterales (CRE) infectious diseases. From this, it is clear that the host range of these phages plays a vital role in determining the effectiveness of any phage therapy, and this factor is usually analyzed based on the advantages and limitations of different host ranges. There have also been efforts to expand phage host ranges via phage cocktail development, phage engineering and combination therapies, in line with current technological advancements. This literature review aims to provide a more in-depth understanding of the role of phage host ranges in the effectiveness of treating MDR-bacterial diseases, by exploring the following: phage biology, the importance of phages in MDR bacteria diseases treatment, the importance of phage host range and its advantages and limitations, current findings and recent developments, and finally, possible future directions for wide host range phages.

Keywords: broad host range; monovalent; multidrug-resistant (MDR) bacteria; narrow host range; phage host range; polyvalent.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
A flow diagram showing general phage–host interactions (a) lytic cycle, (b) chronic cycle, (c) lysogenic cycle, (d) pseudolysogenic cycle. Adapted from “Lytic and Lysogenic Cycle”, by BioRender.com (2021). Retrieved from https://app.biorender.com/biorender-templates (accessed on 23 May 2023).

Similar articles

Cited by

References

    1. Tommasi R., Brown D.G., Walkup G.K., Manchester J.I., Miller A.A. ESKAPEing the labyrinth of antibacterial discovery. Nat. Rev. Drug Discov. 2015;14:529–542. doi: 10.1038/nrd4572. - DOI - PubMed
    1. Reygaert W.C. An overview of the antimicrobial resistance mechanisms of bacteria. AIMS Microbiol. 2018;4:482–501. doi: 10.3934/microbiol.2018.3.482. - DOI - PMC - PubMed
    1. Tanwar J., Das S., Fatima Z., Hameed S. Multidrug Resistance: An Emerging Crisis. Interdiscip. Perspect. Infect. Dis. 2014;2014:541340. doi: 10.1155/2014/541340. - DOI - PMC - PubMed
    1. World Health Organization Antimicrobial Resistance. [(accessed on 6 May 2023)];2021 Available online: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistanc....
    1. Paul V.D., Sundarrajan S., Rajagopalan S.S., Hariharan S., Kempashanaiah N., Padmanabhan S., Sriram B., Ramachandran J. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 2011;11:195. doi: 10.1186/1471-2180-11-195. - DOI - PMC - PubMed

LinkOut - more resources